Adularia AG
Precision Cancer Immunotherapy
At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages. By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the bodys native immune response against cancer.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
08.04.2025
University Hospital Zurich's Health Innovation Hub expands portfolio (startupticker.ch)
06.09.2024
Kickfund invests at full throttle (startupticker.ch)
27.04.2023
The Biomedical Entrepreneurship ecosystem: Turning cutting-edge research into viable ventures (venturelab.swiss)
Last Tweets
No Jobs
Documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Biotech
Adularia AG
Precision Cancer Immunotherapy
Website:
www.adularia.ch
Headquarter:
Zurich ETH Zentrum
Foundation Date:
September 2022
Technology:
- Biotech
Sectors:
- Cancer
- Drug discovery
- Small molecule drugs
Support received
